Do analysts prefer OMCL or MDRX?

Omnicell presently has a consensus price target of $59.86, suggesting a potential upside of 38.17%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts clearly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.66 $2.05M $0.44 98.45 Veradigm $1.53B 0.39 N/A N/A N/A

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Veradigm N/A N/A N/A

Does the media prefer OMCL or MDRX?

In the previous week, Veradigm had 1 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Veradigm and 3 mentions for Omnicell. Omnicell's average media sentiment score of 1.04 beat Veradigm's score of 0.34 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradigm 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HSTM or MDRX?

HealthStream presently has a consensus price target of $24.00, indicating a potential downside of 5.62%. Given HealthStream's stronger consensus rating and higher possible upside, equities research analysts clearly believe HealthStream is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthStream 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, HSTM or MDRX?

HealthStream has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthStream $304.06M 2.44 $18.34M $0.67 37.96 Veradigm $1.53B 0.39 N/A N/A N/A

Which has higher valuation & earnings, MDRX or CNGL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.39 N/A N/A N/A Canna-Global Acquisition N/A N/A N/A N/A N/A

Is MDRX or CNGL more profitable?

Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Canna-Global Acquisition N/A N/A N/A

Do analysts rate FUSE or MDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fusemachines 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, FUSE or MDRX?

Veradigm has higher revenue and earnings than Fusemachines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fusemachines $7.71M 5.27 -$930K -$0.03 N/A Veradigm $1.53B 0.39 N/A N/A N/A

Is FUSE or MDRX more profitable?

Company Net Margins Return on Equity Return on Assets Fusemachines N/A N/A N/A Veradigm N/A N/A N/A

Does the media prefer FUSE or MDRX?

In the previous week, Veradigm had 1 more articles in the media than Fusemachines. MarketBeat recorded 4 mentions for Veradigm and 3 mentions for Fusemachines. Fusemachines' average media sentiment score of 1.89 beat Veradigm's score of 0.34 indicating that Fusemachines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fusemachines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Veradigm 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, OMQS or MDRX?

Veradigm has higher revenue and earnings than OMNIQ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OMNIQ $81.19M 0.02 -$29.43M $0.11 1.00 Veradigm $1.53B 0.39 N/A N/A N/A

Is OMQS or MDRX more profitable?

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%. Company Net Margins Return on Equity Return on Assets OMNIQ -34.33% N/A -61.97% Veradigm N/A N/A N/A

Veradigm (MDRX) Competitors

$5.00 0.00 (0.00%)

As of 05/29/2026 04:00 PM Eastern

Compare

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

Should you buy Veradigm stock or one of its competitors? MarketBeat compares Veradigm with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradigm include Omnicell (OMCL), HealthStream (HSTM), Canna-Global Acquisition (CNGL), Fusemachines (FUSE), and OMNIQ (OMQS).

How does Veradigm compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.66	$2.05M	$0.44	98.45
Veradigm	$1.53B	0.39	N/A	N/A	N/A

In the previous week, Veradigm had 1 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Veradigm and 3 mentions for Omnicell. Omnicell's average media sentiment score of 1.04 beat Veradigm's score of 0.34 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

Omnicell has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Omnicell presently has a consensus price target of $59.86, suggesting a potential upside of 38.17%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts clearly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Omnicell beats Veradigm on 13 of the 15 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

HealthStream presently has a consensus price target of $24.00, indicating a potential downside of 5.62%. Given HealthStream's stronger consensus rating and higher possible upside, equities research analysts clearly believe HealthStream is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

HealthStream has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.44	$18.34M	$0.67	37.96
Veradigm	$1.53B	0.39	N/A	N/A	N/A

In the previous week, Veradigm had 3 more articles in the media than HealthStream. MarketBeat recorded 4 mentions for Veradigm and 1 mentions for HealthStream. HealthStream's average media sentiment score of 1.87 beat Veradigm's score of 0.34 indicating that HealthStream is being referred to more favorably in the media.

Company	Overall Sentiment
HealthStream	Very Positive
Veradigm	Neutral

69.6% of HealthStream shares are owned by institutional investors. 20.4% of HealthStream shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HealthStream has a net margin of 6.39% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.47% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.39%	6.47%	4.44%
Veradigm	N/A	N/A	N/A

HealthStream has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Summary

HealthStream beats Veradigm on 10 of the 13 factors compared between the two stocks.

How does Veradigm compare to Canna-Global Acquisition?

Veradigm (NASDAQ:MDRX) and Canna-Global Acquisition (NASDAQ:CNGL) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.39	N/A	N/A	N/A
Canna-Global Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Veradigm had 4 more articles in the media than Canna-Global Acquisition. MarketBeat recorded 4 mentions for Veradigm and 0 mentions for Canna-Global Acquisition. Veradigm's average media sentiment score of 0.34 beat Canna-Global Acquisition's score of 0.00 indicating that Veradigm is being referred to more favorably in the media.

Company	Overall Sentiment
Veradigm	Neutral
Canna-Global Acquisition	Neutral

Veradigm has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Canna-Global Acquisition has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

19.5% of Canna-Global Acquisition shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 72.1% of Canna-Global Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Canna-Global Acquisition	N/A	N/A	N/A

Summary

Veradigm beats Canna-Global Acquisition on 4 of the 6 factors compared between the two stocks.

How does Veradigm compare to Fusemachines?

Fusemachines (NASDAQ:FUSE) and Veradigm (NASDAQ:MDRX) are both small-cap computer integrated systems design industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Veradigm had 1 more articles in the media than Fusemachines. MarketBeat recorded 4 mentions for Veradigm and 3 mentions for Fusemachines. Fusemachines' average media sentiment score of 1.89 beat Veradigm's score of 0.34 indicating that Fusemachines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fusemachines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fusemachines has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Veradigm has higher revenue and earnings than Fusemachines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fusemachines	$7.71M	5.27	-$930K	-$0.03	N/A
Veradigm	$1.53B	0.39	N/A	N/A	N/A

46.8% of Fusemachines shares are owned by institutional investors. 31.8% of Fusemachines shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Fusemachines	N/A	N/A	N/A
Veradigm	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fusemachines	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Fusemachines beats Veradigm on 6 of the 9 factors compared between the two stocks.

How does Veradigm compare to OMNIQ?

OMNIQ (NASDAQ:OMQS) and Veradigm (NASDAQ:MDRX) are both small-cap computer integrated systems design industry companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%.

Company	Net Margins	Return on Equity	Return on Assets
OMNIQ	-34.33%	N/A	-61.97%
Veradigm	N/A	N/A	N/A

5.7% of OMNIQ shares are held by institutional investors. 11.6% of OMNIQ shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Veradigm had 4 more articles in the media than OMNIQ. MarketBeat recorded 4 mentions for Veradigm and 0 mentions for OMNIQ. Veradigm's average media sentiment score of 0.34 beat OMNIQ's score of 0.00 indicating that Veradigm is being referred to more favorably in the news media.

Company	Overall Sentiment
OMNIQ	Neutral
Veradigm	Neutral

OMNIQ has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Veradigm has higher revenue and earnings than OMNIQ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OMNIQ	$81.19M	0.02	-$29.43M	$0.11	1.00
Veradigm	$1.53B	0.39	N/A	N/A	N/A

Summary

Veradigm beats OMNIQ on 7 of the 10 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Computer integrated systems design Industry	Business Sector	NASDAQ Exchange
Market Cap	$602M	$1.06B	$6.77B	$12.61B
Dividend Yield	N/A	3.99%	3.01%	5.31%
P/E Ratio	23.25	2.33	29.95	26.66
Price / Sales	0.39	1.89	424.97	114.72
Price / Cash	N/A	N/A	23.12	37.60
Price / Book	N/A	N/A	6.00	6.91
Net Income	N/A	-$15.18M	$204.49M	$336.84M
7 Day Performance	5.26%	-2.95%	6.18%	3.97%
1 Month Performance	N/A	N/A	-8.44%	-0.58%
1 Year Performance	16.82%	-1.04%	42.40%	40.17%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$5.00 flat	N/A	+16.8%	$602M	$1.53B	23.25	8,000	Gap Down
OMCL Omnicell	3.7587 of 5 stars	$44.52 +0.2%	$59.86 +34.5%	+46.1%	$2.02B	$1.18B	101.18	3,580
HSTM HealthStream	2.9714 of 5 stars	$23.86 +0.2%	$24.00 +0.6%	-11.1%	$697.19M	$304.06M	35.61	1,160	Positive News
CNGL Canna-Global Acquisition	N/A	$9.00 flat	N/A	N/A	$59.49M	N/A	N/A	2
FUSE Fusemachines	0.7313 of 5 stars	$1.45 +2.8%	N/A	N/A	$41.96M	$7.71M	N/A	317	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Summary

How does Veradigm compare to HealthStream?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Summary

How does Veradigm compare to Fusemachines?

Summary

How does Veradigm compare to OMNIQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Which has stronger earnings & valuation, OMCL or MDRX?

Does the media prefer OMCL or MDRX?

Is OMCL or MDRX more profitable?

Which has more risk & volatility, OMCL or MDRX?

Do analysts prefer OMCL or MDRX?

Do insiders & institutionals hold more shares of OMCL or MDRX?

Summary

How does Veradigm compare to HealthStream?

Do analysts recommend HSTM or MDRX?

Which has better valuation & earnings, HSTM or MDRX?

Does the media prefer HSTM or MDRX?

Do insiders and institutionals believe in HSTM or MDRX?

Is HSTM or MDRX more profitable?

Which has more volatility & risk, HSTM or MDRX?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Which has higher valuation & earnings, MDRX or CNGL?

Does the media prefer MDRX or CNGL?

Which has more risk and volatility, MDRX or CNGL?

Do institutionals and insiders hold more shares of MDRX or CNGL?

Is MDRX or CNGL more profitable?

Summary

How does Veradigm compare to Fusemachines?

Does the media prefer FUSE or MDRX?

Which has more risk & volatility, FUSE or MDRX?

Which has stronger valuation & earnings, FUSE or MDRX?

Do insiders & institutionals have more ownership in FUSE or MDRX?

Is FUSE or MDRX more profitable?

Do analysts rate FUSE or MDRX?

Summary

How does Veradigm compare to OMNIQ?

Is OMQS or MDRX more profitable?

Do institutionals and insiders believe in OMQS or MDRX?

Does the media prefer OMQS or MDRX?

Which has more risk and volatility, OMQS or MDRX?

Which has stronger earnings and valuation, OMQS or MDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools